Cilag raises €2.5M Series B round
20 February 2014· Schaffhausen, Switzerland· pharmaceuticals, manufacturing, biotech, b2b, software_hardware
To primarily support the clinical development of Covagen's lead FynomAb COVA322, a bispecific TNF/IL-17A inhibitor.
Investors
LeadBaxter Ventures
About Cilag
Stage
Series B
Headquarters
Schaffhausen, Switzerland
Founded
1936
Team Size
500+
Sectors
pharmaceuticalsmanufacturingbiotechb2bsoftware_hardware